NCT04418167 - JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Solid Tumors

Interventions

DRUG

JSI-1187

JSI-1187 capsules for oral administration

DRUG

Dabrafenib

Dabrafenib capsules for oral administration

Trial Locations (7)

Mayo Clinic Cancer Center, Jacksonville

Mayo Clinic Cancer Center, Rochester

Mayo Clinic Cancer Center, Phoenix

University of Arizona Comprehensive Cancer Center, Tucson

University of California Helen Diller Family Comprehensive Cancer Center, San Francisco

Massachusetts General Hospital Cancer Center, Boston

Dana Farber Cancer Institute, Boston